# Rifaximin Versus Lactulose in Renal Failure

> **NCT00748904** · PHASE4 · WITHDRAWN · sponsor: **Weill Medical College of Cornell University**

## Conditions studied

- Liver Cirrhosis
- Renal Failure

## Interventions

- **DRUG:** Rifaximin
- **DRUG:** Lactulose

## Key facts

- **NCT ID:** NCT00748904
- **Lead sponsor:** Weill Medical College of Cornell University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2008-06
- **Primary completion:** 2009-07
- **Final completion:** 2009-07
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2022-02-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00748904

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00748904, "Rifaximin Versus Lactulose in Renal Failure". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00748904. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*